NasdaqGM - Delayed Quote USD
Ikena Oncology, Inc. (IKNA)
1.1100
0.0000
(0.00%)
At close: May 19 at 4:00:00 PM EDT
1.1100
0.00
(0.00%)
After hours: May 19 at 4:00:09 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Mark Manfredi Ph.D. | President, CEO & Director | 868.19k | -- | 1972 |
| Dr. Jotin Marango M.D., Ph.D. | COO, CFO, Head of Corporate Development & Treasurer | 809.95k | -- | 1980 |
| Ms. Rebecca Cohen | Senior VP of Investor Relations, Corporate Strategy & Communication | -- | -- | -- |
| Mr. Jeffrey Ecsedy Ph.D. | Chief Development Officer | -- | -- | 1970 |
| Mr. Bob Lally | Senior Vice President of Finance & Operations | -- | -- | -- |
| Mr. David Damphousse M.S. | Senior Vice President of Clinical Development Operations | -- | -- | -- |
Ikena Oncology, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 9
Description
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Corporate Governance
Ikena Oncology, Inc.’s ISS Governance QualityScore as of May 1, 2025 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 10; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 6, 2025 at 8:00 PM UTC - August 11, 2025 at 8:00 PM UTC
Ikena Oncology, Inc. Earnings Date
Recent Events
January 10, 2025 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Related Tickers
HLVX HilleVax, Inc.
1.9500
-1.02%
TBPH Theravance Biopharma, Inc.
9.39
+2.07%
IPSC Century Therapeutics, Inc.
0.5543
-1.02%
BOLT Bolt Biotherapeutics, Inc.
0.3277
+11.84%
PMVP PMV Pharmaceuticals, Inc.
0.8740
+0.94%
CRGX CARGO Therapeutics, Inc.
4.0900
-0.73%
EPIX ESSA Pharma Inc.
1.7000
-0.58%
ANTX AN2 Therapeutics, Inc.
1.1900
-1.65%
KZR Kezar Life Sciences, Inc.
4.0300
-0.98%
DSGN Design Therapeutics, Inc.
3.5300
+0.57%